ASHNHL16

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
Taken together, it is estimated that approximately 162,020 new lymphoid, myeloid and leukemic cancer cases were identified in the United States in the year 2015, and 56,630 individuals died from these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, comprising more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses quite a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These proceedings from a CME symposium during the 57^th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of Hodgkin and non-Hodgkin lymphoma (NHL). By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

Appraise recent data on therapeutic advances and changing practice standards in the management of Hodgkin lymphoma (HL) and NHL, including chronic lymphocytic leukemia (CLL), and integrate this information, as appropriate, into current clinical care.
Appreciate the recent FDA approvals of novel targeted agents — ibrutinib, idelalisib and obinutuzumab — for the treatment of newly diagnosed and relapsed/refractory CLL, and discern how these therapies can be appropriately integrated into routine clinical practice.
Customize the selection of systemic therapy for patients with newly diagnosed and progressive mantle-cell lymphoma, recognizing the recent addition of bortezomib, lenalidomide and ibrutinib as FDA-endorsed options.
Consider available clinical research reports in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory follicular and diffuse large B-cell lymphoma.
Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and ensure appropriate supportive care measures to minimize side effects from these therapies.
Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
Incorporate new therapeutic strategies into the best-practice management of HL.
Develop an understanding of the biologic rationale for and early efficacy and toxicity data with the use of immunotherapeutic approaches for patients with various lymphoma subtypes.
Assess the ongoing clinical trials evaluating innovative investigational approaches for NHL and HL, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Martin Dreyling, MD, PhD
Professor of Medicine
Department of Medicine III
University Hospital – LMU Munich
Munich, Germany

Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc; Speaker Honorarium: Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc; Support of IITS: Celgene Corporation, Janssen Biotech Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc.

Christopher Flowers, MD, MS
Associate Professor of Hematology and Medical Oncology
Emory School of Medicine
Winship Cancer Institute
Atlanta, Georgia

Consulting Agreements: Celgene Corporation, OptumRx Inc, Seattle Genetics, Spectrum Pharmaceuticals Inc; Contracted Research: Acerta Pharma, Celgene Corporation, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology; Unpaid Consulting Agreements: Genentech BioOncology, Takeda Oncology.

Owen A O’Connor, MD, PhD
Professor of Medicine and Developmental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
College of Physicians and Surgeons
NewYork-Presbyterian Hospital
New York, New York

Advisory Committee: Mundipharma International Limited, Takeda Oncology; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Mundipharma International Limited, Spectrum Pharmaceuticals Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology.

Sonali M Smith, MD
Associate Professor
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Consulting Agreements: Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, ImmunogeniX Research LLC, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Data and Safety Monitoring Board: Genentech BioOncology.

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
University of Virginia School of Medicine
Charlottesville, Virginia

Advisory Committee: Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology.

Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Sanofi; Contracted Research: Novartis Pharmaceuticals Corporation; Honorarium: Incyte Corporation, Janssen Biotech Inc, Seattle Genetics, Takeda Oncology; Research Support: Curis Inc, Johnson & Johnson Pharmaceuticals.

CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Margaret A Deutsch, MD
Clinical Associate
Duke Raleigh Hematology-Oncology
Raleigh, North Carolina